Fabhale™
Formoterol Fumarate & Budesonide · Powder for Inhalation I.P.
The Respiratory Crisis Across India
Asthma and COPD together represent India's most significant non-communicable disease burden — and cost-driven non-adherence is the central clinical challenge.
- Asthma affects an estimated 30 million people across India; COPD affects tens of millions more — driven by indoor air pollution, biomass fuels, occupational dust, and tobacco use
- Despite this scale, inhaler penetration remains critically low vs. global averages — cost is the primary driver of non-adherence in study after study
- Patients who cannot sustain maintenance therapy cycle through rescue medication, emergency visits, and progressive irreversible decline in lung function
- A high-strength combination inhaler at open-market pricing (₹391) forces lower-income patients to choose between medication and food — the cycle begins
Dual Mechanism of Action
Fabhale combines two gold-standard molecules in a single DPI capsule, delivering synergistic bronchodilation and sustained anti-inflammation — exceeding the effect of either drug alone.
Selective β₂-agonist that relaxes airway smooth muscle by increasing intracellular cAMP — widening both large and small airways. Unique among LABAs for its fast onset combined with prolonged duration.
- Onset of action: <3 minutes
- Duration: up to 12 hours (BD dosing)
- Suitable for MART / AIR strategy
- Acts on large and peripheral small airways
Inhibits inflammatory mediators — cytokines, leukotrienes, prostaglandins. Reduces mucosal oedema and airway hyperresponsiveness, addressing disease at its root cause, not just symptoms. Rapid nongenomic action onset demonstrated.
- Reduces airway hyperresponsiveness
- Suppresses chronic mucosal inflammation
- Lowers systemic corticosteroid burden
- One of the most evidence-backed ICS molecules globally
Key Trial Data & Outcomes
The efficacy of budesonide-formoterol is supported by landmark trials, large meta-analyses, and Cochrane systematic reviews.
GINA 2024/25; SYGMA 1 & 2 Trials, NEJM 2019
Meta-analysis, JAMA Intern Med 2022 (n=4,863)
Cochrane SR PMC10357488 (2023); Bayu clinical data
Guideline-Mandated First Choice
GINA 2024/25 represents the most significant paradigm shift in asthma management in decades. Budesonide-formoterol DPI is the specifically cited, evidence-based preferred formulation.
- SABAs alone are no longer recommended as reliever therapy at any step for adults and adolescents
- All patients must receive ICS-containing medication — either as regular maintenance or in every reliever dose
- Track 1 (Preferred): ICS-formoterol as both maintenance AND reliever (MART/AIR strategy) — applicable at Steps 1 through 4
- Budesonide-formoterol DPI is specifically cited in GINA, BTS/NICE/SIGN 2024 as the evidence-based preferred formulation for SMART regimens
| GINA Step | Disease Severity | Recommended Fabhale | Strategy |
|---|---|---|---|
| Step 1 | Mild intermittent | Fabhale 200 200 mcg | AIR: Low-dose ICS-formoterol as-needed reliever only — no SABA recommended |
| Step 2 | Mild persistent | Fabhale 200 200 mcg | AIR: Low-dose ICS-formoterol as-needed OR low-dose ICS daily + SABA PRN |
| Step 3 | Moderate persistent | Fabhale 200/400 200/400 mcg | MART: Low-dose ICS-formoterol maintenance AND as-needed reliever |
| Step 4 | Moderate–severe persistent | Fabhale 400 400 mcg | MART: Medium-dose ICS-formoterol maintenance AND as-needed reliever |
Benefits of Dry Powder Inhaler Delivery
The OptiHaler DPI device used with Fabhale offers distinct clinical and practical advantages over pressurised MDI systems.
| DPI Advantage | Clinical Significance |
|---|---|
| Direct pulmonary deposition | Drug delivered straight to the site of action — minimal systemic absorption, lower side-effect burden |
| Breath-actuated device | No hand-breath coordination required; suitable for elderly patients and those with poor coordination |
| CFC-free / no propellant | Environmentally friendly; consistent dose delivery independent of ambient temperature and humidity |
| Compact & portable | High patient acceptability; encourages daily adherence and maintenance therapy compliance |
| Capsule-based OptiHaler | Patients hear and feel the capsule spin — audible and tactile confirmation of dose delivery, improving technique confidence |
| Fine particle size | Reaches small peripheral airways — superior distribution across large and distal lung segments |
Inhaler Technique — OptiHaler DPI
Dosing Guide & Affordability Comparison
Both Fabhale strengths vs. the open-market equivalent — same molecule, proven outcomes, dramatically different cost.
| Parameter | Fabhale™ 200 | Fabhale™ 400 | Competitor Equivalent |
|---|---|---|---|
| Composition | Formoterol 6 mcg + Budesonide 200 mcg | Formoterol 6 mcg + Budesonide 400 mcg | Formoterol 6 mcg + Budesonide 400 mcg |
| MRP (30 caps) | ₹99 | ₹150 62% lower cost |
₹391 |
| Asthma | Mild–Moderate: 1 cap BD + 1 cap as needed for relief | Moderate–Severe: 1 cap BD + 1 cap as needed for relief | Moderate–Severe |
| COPD | Mild–Moderate: 1 cap BD; escalate per GOLD guidelines | Moderate–Severe: 1 cap BD; preferred in frequent exacerbators | Moderate–Severe |
| MART / AIR | 1 cap PRN (Steps 1–2); 1 cap BD + PRN (Step 3) | 1 cap BD + as needed (GINA Steps 3–4) | 1 cap BD + as needed |
| Device | OptiHaler DPI — capsule NOT for swallowing · rinse mouth after each use (Fabhale 400) | Various DPI devices | |
#RTI — Right to Inhalation
A Bayu Healthcare initiative rooted in a single clinical truth: a prescription that cannot be filled does not heal. Cost is the number one cause of inhaler non-adherence in India.
What began as a pricing decision has grown into a movement — working with doctors, pharmacists, healthcare workers, and ASHA volunteers across India to close the gap between what doctors prescribe and what patients can actually afford.
At ₹391 per inhaler, lower-income patients face an impossible choice — buy medicine or buy food. When symptoms ease, medication is the first casualty.
The cycle: symptoms return → emergency care → brief relief → medication abandoned → repeat.
A life half-lived, punctuated by crises that could have been prevented. For lakhs of patients across rural India, this cycle continues today.
Fabhale 400 delivers the same Formoterol 6 mcg + Budesonide 400 mcg combination — at ₹150 instead of ₹391. Not subsidised. Not compromised. Just fair pricing.
62% lower cost. 100% clinical integrity.
Over 25,000 patients are now on continuous Fabhale therapy across India — with documented improvement in adherence, reduced hospitalisations, and improved quality of life.